Quantcast
Johnson & Johnson Vs. AbbVie: The Better Dividend Aristocrat Buy Might Shock You

Johnson & Johnson Vs. AbbVie: The Better Dividend Aristocrat Buy Might Shock You

Posted On January 6, 2023 8:42 am
By:

2023 is likely to start out weak for stocks, and they could potentially fall 15% to 23% in the coming weeks.

Healthcare is one of only two sectors that historically goes up in recessions, and dividend aristocrat healthcare is the most defensive of all.

Johnson & Johnson and AbbVie Inc. historically fall 70% to 80% less than the S&P 500 Index during bear markets since 1985. Both are great SWAN choices, but one is the far better long-term investment.

One of these aristocrats has superior yield and growth, meaning it offers about 5% higher annual long-term income and return potential than its rival.

Over 30 years, that’s potentially 4x to 5x more inflation-adjusted dividends and total returns over its rival.

That makes it the superior long-term income growth investment from the fair value or better.

Continue Reading Here

About author

Dividend Sensei

I'm an Army veteran and former energy dividend writer for The Motley Fool. I'm a proud co-founder of Wide Moat Research, Dividend Kings, and the Intelligent Dividend Investor. My work can be found on Seeking Alpha, Dividend Kings, iREIT, and the Intelligent Dividend Investor. My goal is to help all people learn how to harness the awesome power of dividend growth investing to achieve their financial dreams and enrich their lives. With 24 years of investing experience, I've learned what works and more importantly, what doesn't, when it comes to building long-term wealth and income streams and achieving long-term financial goals.

Related Articles

Leave a reply

Your email address will not be published. Required fields are marked *